Brief: Ryvu Therapeutics Signs Cooperation, Licence And Investment Deal With BioNTech

Ryvu Therapeutics SA

30/11/2022 06:25

Nov 30 (Reuters) - Ryvu Therapeutics SA  RVU.WA :
    * SIGNS RESEARCH COOPERATION DEAL, EXCLUSIVE LICENCE DEAL
AND
INVESTMENT DEAL WITH BIONTECH
    * PARTIES TO DEVELOP SMALL MOLECULE COMPOUNDS FOR THERAPY
FOCUSED
MAINLY ON IMMUNOLOGICAL MODULATION IN ONCOLOGY
    * REMUNERATION AT EUR 20.0 MILLION FOR GLOBAL, EXCLUSIVE
LICENSE
TO DEVELOP AND COMMERCIALIZE A PORTFOLIO OF STAND-ALONE
SMALL-MOLECULE STING AGONISTS
    * REMUNERATION ALSO FOR RIGHT TO OBTAIN EXCLUSIVE LICENSE
FOR
SEVERAL PROGRAMS WITHIN FRAMEWORK OF RESEARCH COOPERATION
COVERING MANY THERAPEUTIC PURPOSES
    * ACCORDING TO LICENSE AGREEMENT, BIONTECH WILL FINANCE ALL
RESEARCH AND DEVELOPMENT COSTS AS PART OF COOPERATION
    * COMPANY WILL BE ENTITLED TO GET PAYMENT OF UP TO EUR 876.2
MILLION FOR POTENTIAL MILESTONES
    * AMOUNT OF UP TO EUR 876.2 MILLION IS BIO-EURO VALUE
    * UNDER INVESTMENT AGREEMENT, BIONTECH TO INVEST FURTHER EUR
20.0
MILLION BY ACQUISITION OF NEW J-SERIES SHARES
    * BIONTECH TO HAVE PRIORITY RIGHT FOR NEGOTIATIONS ON ANY OF
COMPANY'S ONCOLOGICAL MODULATION PROJECTS BEYOND SCOPE OF
PARTNERSHIP DEAL
    * PRIORITY RIGHT TO RUN FOR FIVE YEARS FROM LICENCE DEAL OR
TILL
SELECTION OF BIONTECH EXCLUSIVE THERAPEUTIC GOALS
    * INITIAL PERIOD OF COOPERATION IS FIVE YEARS AND MAY BE
EXTENDED

Source text for Eikon:  ID:nEM38Z9Sxa 
Further company coverage:  RVU.WA 
 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))